MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

Home・Elenco Azioni・BioNTech SE ADR

BioNTech SE ADR

Chiusa

SettoreSettore sanitario

88 -4.23

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

86.18

Massimo

91.9

Metriche Chiave
By Trading Economics
Entrata	143M 301M
Vendite	-55M 1.2B
EPS	1.08
Margine di Profitto	25.311
Dipendenti	6,772
EBITDA	253M 464M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+49.55% upside

Dividendi
By Dow Jones
Utili prossimi	5 mag 2025

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-3.3B 23B
Apertura precedente	92.23
Chiusura precedente	88

Notizie sul Sentiment di mercato

By Acuity

57%

43%

328 / 386 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

88.78 / 95.61 Supporto e resistenza

BioNTech SE ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

4 feb 2025, 18:52 UTC

I principali Market Mover

Psychedelic Drug Stocks Up, Vaccine Shares Down After Senate Committee Advances RFK Jr.

15 nov 2024, 10:28 UTC

I principali Market Mover

European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department

6 mag 2024, 11:27 UTC

Utili

BioNTech Swings to Net Loss on Lower Covid Vaccine Sales

15 nov 2024, 11:14 UTC

Discorsi di Mercato

U.S. Vaccine Stocks Fall After Trump Picks Vaccine Skeptic RFK Jr as Health Department Head-- Market Talk

15 nov 2024, 10:34 UTC

Discorsi di Mercato

Vaccine Sector Sell-Off Looks Overdone -- Market Talk

5 ago 2024, 10:02 UTC

Utili

BioNTech Sees 2024 R&D Expenses EUR2.4B-EUR2.6B >BNTX

5 ago 2024, 10:01 UTC

Utili

BioNTech Backs 2024 View of Rev EUR2.5B-EUR3.1B >BNTX

5 ago 2024, 10:01 UTC

Utili

BioNTech: Invested EUR525.6M, or About 90% of 2Q R&D Spend, in Non-Covid-19 Related Activities >BNTX

5 ago 2024, 10:00 UTC

Utili

BioNTech 2Q-End Cash, Equivalents, Security Investments EUR18.5 Billion >BNTX

5 ago 2024, 09:59 UTC

Utili

BioNTech 2Q Loss EUR807.8M >BNTX

5 ago 2024, 09:59 UTC

Utili

BioNTech 2Q Loss/Shr EUR3.36 >BNTX

5 ago 2024, 09:59 UTC

Utili

BioNTech 2Q Rev EUR128.7M >BNTX

6 mag 2024, 20:15 UTC

Utili

BioNTech Lifts As Covid Sales Plummet With 90% Of Revenue Still To Come -- IBD

6 mag 2024, 10:47 UTC

Utili

BioNTech Sees FY24 Rev EUR2.5B-EUR3.1B >BNTX

6 mag 2024, 10:46 UTC

Utili

Correct: BioNTech 1Q Loss/Shr EUR1.31 >BNTX

6 mag 2024, 10:46 UTC

Utili

Correct: BioNTech 1Q Loss EUR315.1M >BNTX

6 mag 2024, 10:46 UTC

Utili

Correct: BioNTech 1Q Rev EUR187.6M >BNTX

6 mag 2024, 10:45 UTC

Utili

BioNTech 1Q Rev $187.6M >BNTX

6 mag 2024, 10:45 UTC

Utili

BioNTech 1Q Loss $315.1M >BNTX

6 mag 2024, 10:45 UTC

Utili

BioNTech 1Q Loss/Shr $1.31 >BNTX

Confronto tra pari

Modifica del prezzo

BioNTech SE ADR Previsione

Obiettivo di Prezzo

By TipRanks

49.55% in crescita

Previsioni per 12 mesi

Media 139.56 USD 49.55%

Alto 171 USD

Basso 110 USD

Basato su 17 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per BioNTech SE ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

17 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 17 che hanno fornito valutazioni azionarie a BioNTech SE ADR - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

88.78 / 95.61Supporto e resistenza

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

328 / 386 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo BioNTech SE ADR

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac